TUM – Technical University of Munich Menü

Prof. Dr. Angela Krackhardt

Academic Career and Research Areas

Professor Krackhardt develops adoptive immunotherapies in malignant disease. Her work focuses on the identification and validation of novel tumor-associated antigens, as well as the isolation and characterization of tumor reactive T-lymphocytes and T-cell receptors with specificity for respective antigens, with special emphasis on the identification of neoantigens and the characterization of neoantigen-specific T-cell immune responses. Moreover, she characterizes factors relevant for tumor rejection using novel imaging technologies. Her aim is to implement novel immunotherapies in the clinic that make use of adoptive T-cell therapies with tumor-specific transgenic T-cells.

Professor Krackhardt studied medicine in Berlin and continued her clinical education at the Charité. Her scientific career took her from Berlin, where she started her research within an MD thesis project, to Harvard Medical School in Boston. Following further clinical work at the Charité in Berlin, she continued her scientific work as director of a junior research group at Helmholtz Zentrum Munich and was subsequently appointed to a professorship at TUM.

    Key Publications

    Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi H, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D`Alessandria C, Krackhardt AM: "T-cell functionality testing is highly relevant to develop novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target". Theranostics. 2018; in press.

    Abstract

    Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels W, Schüssler-Lenz M: "Clinical translation and regulatory aspects of CAR/TCR-based adoptive cellular therapies – the German Cancer Consortium Approach". Cancer Immunol Immunother. 2018: 67: 513-523.

    Abstract

    Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM: "Direct identification of clinically relevant neoepitopes presneted on native human melanoma tissue by mass spectrometry". Nature Communications. 2016; 7: 13404.

    Abstract

    Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D`Alessandria C, Krackhardt AM: "Immuno-PET imaging of engineered human T cells in tumors". Cancer Research. 2016; 76: 4113-23.

    Abstract

    Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Stevanovic S, Oostendorp RAJ, Busch DH, Peschel C, Krackhardt AM: "Therapeutic targeting of naturally presented myeloperoxidase derived peptide ligands in myeloid leukemia cells by TCR-transgenic T cells". Leukemia. 2014; 28: 2355-2366.

    Abstract